The infant formula contamination lawsuit is a massive and growing area of litigation in the United States, with 779 cases currently pending in a federal multidistrict litigation (MDL 3026) in the Northern District of Illinois. These lawsuits allege that cow’s milk-based infant formulas — primarily Similac, manufactured by Abbott Laboratories, and Enfamil, manufactured by Mead Johnson — significantly increase the risk of necrotizing enterocolitis (NEC) in premature infants. Jury verdicts have already reached staggering amounts, including a $495 million award in St. Louis in July 2024, and no global settlement has been reached as of March 2026.
Beyond the U.S. NEC litigation, a separate European lawsuit filed in January 2026 by consumer watchdog Foodwatch targets Nestlé, Lactalis, and Danone over cereulide contamination found in an ARA oil ingredient used in infant formula. The scope of formula-related legal action is now international. This article covers the current state of the NEC MDL, key verdicts and what they signal, upcoming trials, estimated settlement values, the European contamination case, and what families should know about filing a claim.
Table of Contents
- What Is the Infant Formula Contamination Lawsuit About and Who Can File?
- Key Verdicts in the NEC Formula Litigation and What They Mean
- Upcoming Federal Trials Set to Shape the Litigation in 2026
- What Are Infant Formula NEC Lawsuit Settlement Amounts Worth?
- The European Infant Formula Contamination Lawsuit — A Different Kind of Case
- How NEC Develops and Why Formula Type Matters
- What Comes Next for the Infant Formula Litigation
- Conclusion
- Frequently Asked Questions
What Is the Infant Formula Contamination Lawsuit About and Who Can File?
The core allegation across these lawsuits is straightforward: Abbott Laboratories and Mead Johnson knew that their cow’s milk-based formulas posed a heightened risk of NEC in premature infants and failed to adequately warn families or healthcare providers. NEC is a devastating intestinal disease that primarily affects preterm babies. It destroys bowel tissue, frequently requires emergency surgery, and can be fatal. The lawsuits claim that decades of medical literature linked cow’s milk-based formula to elevated NEC risk in premature infants, yet manufacturers continued marketing these products to neonatal intensive care units without meaningful warnings.
Families who may be eligible to file typically had a premature infant — generally born before 37 weeks of gestation — who was fed Similac or Enfamil and subsequently developed NEC. The injuries range from surgical NEC requiring bowel resection to short bowel syndrome, long-term feeding difficulties, and death. Abbott alone faces more than 1,700 total lawsuits across courts nationwide, and the number continues to grow as awareness of the litigation increases. It is worth noting that these cases do not allege contamination in the traditional sense of a foreign substance entering the product during manufacturing. Rather, the claim is that the formula itself — specifically its cow’s milk protein base — is inherently dangerous for a vulnerable population and that this danger was concealed.
Key Verdicts in the NEC Formula Litigation and What They Mean
The trial results so far have been dramatic and, importantly, mixed — which matters for anyone trying to gauge where this litigation is headed. In March 2024, an Illinois state court jury awarded $60 million to the mother of an infant who died from NEC after being fed cow’s milk-based formula in a NICU. That verdict put the litigation on the map. Then in July 2024, a St. Louis jury went further, awarding $495 million to the family of a baby girl who developed NEC, one of the largest individual verdicts in recent product liability history. However, the trajectory is not entirely one-sided.
In October 2024, a St. Louis jury sided with both Abbott and Mead Johnson, breaking the streak of plaintiff victories and demonstrating that defense arguments — particularly around causation and the role of prematurity itself in NEC development — can resonate with jurors. Then in December 2025, a plaintiff secured a successful verdict in a federal bellwether trial, which was significant because it was the first win in the MDL’s formal bellwether process. The takeaway is that outcomes remain unpredictable. A strong case with clear evidence of formula exposure and NEC diagnosis does not guarantee a plaintiff verdict, and defense wins do not mean the litigation is collapsing. Each case turns on its own facts, medical records, and the specific infant’s clinical history.
Upcoming Federal Trials Set to Shape the Litigation in 2026
Several major trials are on the calendar for 2026, and their outcomes will likely determine whether a global settlement becomes realistic. A new Abbott Laboratories formula trial began in Cook County, Illinois during the week of March 4, 2026, drawing significant media attention. The case of Inman v. Mead Johnson & Company, LLC, an Enfamil-specific case, is scheduled for trial in July 2026. And a second wave of federal bellwether trials is expected to begin in August 2026, which will test additional case theories and fact patterns before U.S.
District Judge Rebecca Pallmeyer, who presides over the MDL. Bellwether trials serve a specific purpose in mass tort litigation. They are not designed to resolve every case. Instead, they give both sides real-world data on how juries respond to the evidence, which informs settlement negotiations. The December 2025 federal bellwether win for the plaintiff side was a significant data point, but additional trials are needed before either side has enough information to negotiate a comprehensive resolution. For families currently waiting, the practical reality is that individual case resolutions through trial or settlement are unlikely before 2027 at the earliest for most claimants, unless the upcoming trial results create enough pressure to accelerate global settlement talks.
What Are Infant Formula NEC Lawsuit Settlement Amounts Worth?
No global settlement has been reached as of March 2026, so any figures discussed are projections based on verdict trends, comparable mass tort resolutions, and attorney estimates. For non-fatal NEC injuries — cases where a premature infant developed NEC, required surgery, but survived without catastrophic long-term disability — estimated individual payouts range from $50,000 to $600,000. That is a wide range because case value depends heavily on the severity of the injury, the duration of hospitalization, the extent of surgical intervention, and the long-term medical consequences. Cases involving permanent disability, such as short bowel syndrome requiring lifelong parenteral nutrition or repeated surgeries, carry potential settlement values of $1 million to $10 million.
Wrongful death cases, where an infant died from NEC, have produced the largest verdicts at trial and would likely command the highest settlement values. The important caveat is that mass tort settlements almost always pay less than jury verdicts. A $495 million verdict does not translate to a $495 million settlement payment. Settlement grids typically tier cases by injury severity, and the final payout per claimant depends on how many total cases are in the settlement pool and how much the defendants are willing to pay to achieve global peace. Families should discuss realistic expectations with their attorney rather than anchoring to headline verdict numbers.
The European Infant Formula Contamination Lawsuit — A Different Kind of Case
While the U.S. litigation focuses on the inherent NEC risk of cow’s milk-based formula, a separate and distinct legal battle is unfolding in Europe. In January 2026, Foodwatch, a European consumer watchdog organization, filed a lawsuit targeting Nestlé, Lactalis, and Danone over cereulide contamination found in an ARA oil ingredient used in infant formula sold across multiple European markets. Cereulide is a toxin produced by Bacillus cereus bacteria, and its presence in an ingredient used in infant formula is a traditional contamination case — a harmful substance that should not have been in the product. Foodwatch’s core allegation is not just that contamination occurred, but that manufacturers and regulatory authorities delayed recalls after the contamination was identified.
According to the complaint, affected products remained on shelves and were sold to families for months before warnings were issued. This is a fundamentally different legal theory than the U.S. NEC cases. It does not require proving that formula itself is dangerous — only that a specific batch was contaminated and that the response was inadequate. For European families, this case raises serious questions about supply chain oversight and regulatory responsiveness. However, this litigation is in its early stages, and it remains unclear what remedies Foodwatch is seeking or whether individual families will be able to claim compensation through this action.
How NEC Develops and Why Formula Type Matters
NEC occurs when bacteria invade the wall of the intestine, causing inflammation, tissue death, and in severe cases, perforation of the bowel. It overwhelmingly affects premature infants, particularly those born before 32 weeks of gestation and weighing less than 1,500 grams. The medical literature has for decades noted a correlation between exclusive formula feeding and higher NEC rates compared to breast milk feeding. Human breast milk contains immunoglobulins, growth factors, and beneficial bacteria that help protect the immature gut, protections that cow’s milk-based formula does not replicate.
The plaintiffs’ argument rests on this body of research. They contend that Abbott and Mead Johnson were aware of studies showing elevated NEC risk in formula-fed preterm infants and had an obligation to warn NICUs and parents. The defense counters that NEC is a multifactorial disease, that prematurity itself is the dominant risk factor, and that formula feeding is sometimes medically necessary when breast milk is unavailable. This causation debate is the central battleground in every trial, and the mixed verdict results reflect genuine scientific complexity rather than a clear-cut answer.
What Comes Next for the Infant Formula Litigation
The next twelve to eighteen months will be decisive. If the 2026 bellwether trials produce additional plaintiff verdicts with substantial damages, Abbott and Mead Johnson will face mounting financial and reputational pressure to negotiate a global settlement. If defense verdicts become more common, the calculus shifts, and plaintiffs may need to adjust expectations. The Cook County trial that began in early March 2026, the Inman v.
Mead Johnson trial in July, and the second federal bellwether wave in August will collectively provide the clearest picture yet of where this litigation is heading. For families still considering whether to file, the statute of limitations varies by state, and some states have discovery rules that toll the filing deadline until the connection between formula and NEC is known or should have been known. Waiting too long carries real risk. Attorneys handling these cases typically work on contingency, meaning families pay nothing upfront and the attorney takes a percentage only if there is a recovery. Given the scale of the litigation and the strength of early verdicts, this remains one of the most significant product liability cases in the country.
Conclusion
The infant formula contamination lawsuit — encompassing the massive NEC MDL in Illinois, state court cases across the country, and the emerging European cereulide contamination action — represents a reckoning for formula manufacturers who allegedly prioritized market share over infant safety. With 779 federal cases pending, more than 1,700 total lawsuits against Abbott alone, and jury verdicts reaching $495 million, the financial exposure for defendants is enormous. Yet the October 2024 defense verdict is a reminder that nothing is guaranteed at trial.
Families of premature infants who developed NEC after being fed Similac or Enfamil should consult with an attorney experienced in this specific litigation to evaluate their case. The window to file remains open in most jurisdictions, but it will not stay open indefinitely. As bellwether trials continue through 2026, the path toward either a global settlement or prolonged case-by-case litigation will become clearer. In the meantime, the verdicts already on the books have sent an unmistakable message about how juries view manufacturers’ failure to warn.
Frequently Asked Questions
What is NEC and why is it linked to infant formula?
Necrotizing enterocolitis is a serious intestinal disease that primarily affects premature infants. Bacteria invade the intestinal wall, causing tissue death and potentially fatal complications. Medical research has shown that premature infants fed cow’s milk-based formula develop NEC at significantly higher rates than those fed human breast milk, which contains protective immunological factors.
Which infant formula brands are named in the lawsuit?
The primary defendants are Abbott Laboratories, which manufactures Similac, and Mead Johnson (now owned by Reckitt Benckiser), which manufactures Enfamil. Both companies’ cow’s milk-based formula products are at the center of the NEC litigation.
How much could I receive from an infant formula NEC settlement?
No global settlement exists yet as of March 2026. Estimated projections based on verdicts and attorney analysis suggest $50,000 to $600,000 for non-fatal NEC injuries and $1 million to $10 million for cases involving permanent disability. Wrongful death cases may command even higher values. Actual amounts will depend on individual case facts and any eventual settlement structure.
Is there a deadline to file an infant formula NEC lawsuit?
Yes. Statutes of limitations vary by state, typically ranging from two to six years from the date of injury or discovery. Some states have specific rules for minors that extend the deadline. Because these deadlines vary and can be complex, consulting an attorney promptly is critical to preserving your right to file.
What is the European infant formula lawsuit about?
In January 2026, consumer watchdog Foodwatch filed a lawsuit against Nestlé, Lactalis, and Danone over cereulide contamination found in an ARA oil ingredient used in infant formula across European markets. The allegation centers on delayed recalls that left contaminated products on shelves for months. This is a separate case from the U.S. NEC litigation.
How long will the NEC lawsuit take to resolve?
The litigation is still in its bellwether trial phase. A second wave of federal bellwether trials is expected to begin in August 2026. Most legal analysts believe a global settlement, if one is reached, would not be finalized before 2027 at the earliest. Individual case timelines depend on jurisdiction, case strength, and trial scheduling.